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Abstract: The role of zinc finger and BTB domain containing 7A (ZBTB7A) in oncogenesis has been shown to be 
context-dependent, participating in pro-oncogenic or oncosuppressive mechanisms by directly regulating gene tran-
scription or by interacting with other regulatory proteins. Alterations in ZBTB7A expression have been associated 
with worse prognosis. We examined ZBTB7A protein expression in breast carcinoma tissue samples and analyzed 
its clinical and prognostic significance. Tissue microarray blocks from 196 cases of invasive ductal carcinoma (IDC) 
were immunostained and <65% positively stained tumor cell nuclei were defined as low ZBTB7A expression. Of 196 
IDC cases, 120 (61.2%) showed low ZBTB7A expression. Low nuclear ZBTB7A expression was associated with larger 
tumor size, higher histological grade, estrogen receptor negativity, progesterone receptor negativity, triple negativity, 
and recurrence. Cytoplasmic ZBTB7A expression was not associated with any clinicopathological characteristics. 
In univariate survival analysis, nuclear ZBTB7A expression did not affect overall or recurrence-free survival. How-
ever, multivariate survival analysis revealed that ZBTB7A independently predicted recurrence-free survival of IDC 
patients. Reduced ZBTB7A expression is associated with aggressive oncogenic behavior of IDC. ZBTB7A expression 
may be a novel prognostic biomarker for predicting recurrence-free survival of IDC patients.
Keywords: Breast, invasive ductal carcinoma, zinc finger and BTB domain containing 7A, immunohistochemistry, 
prognosis
Introduction
Zinc finger and BTB domain containing 7A 
(ZBTB7A; also known as factor that binds to 
inducer of short transcripts protein 1, Pokemon, 
leukemia/lymphoma-related factor, and osteo-
clast-derived zinc finger) is a member of the 
BTB/poxvirus and zinc finger, and Kruppel 
(POK) family of transcription factors. Through 
the zinc finger domain, POK proteins bind to a 
specific consensus sequence in the target gene 
promoter to regulate transcription. The BTB 
domain enables homodimer formation and 
interaction with co-repressor proteins such as 
BCL6, a silencing mediator of retinoid and thy-
roid receptors, and mSin3A which is a histone 
deacetylase that contributes to transcriptional 
repression by POK proteins [1, 2]. For ZBTB7A, 
the list of BTB domain-interacting proteins in- 
cludes BCL6, specificity protein 1, and andro-
gen receptor [2]. Being a transcription factor 
and having a nuclear localization signal at the 
C-terminal, ZBTB7A is often detected predomi-
nantly in the nucleus [3-8].
ZBTB7A plays developmental roles as demon-
strated in the differentiation of hemato-lym-
phoid cells, chondrocytes, adipocytes, and os- 
teoclasts [1, 2]. Moreover, ZBTB7A mRNA and 
protein A have been identified in both normal 
and cancerous tissues of multiple organs. 
Increased ZBTB7A expression has been recog-
nized in diffuse large B-cell lymphoma and car-
cinomas of the colon, stomach, lung, ovary, 
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liver, prostate, and breast [4, 5, 7, 9-12]. A neg-
ative prognostic effect of high ZBTB7A expres-
sion has been reported in carcinomas of the 
stomach, lung, ovary, liver, and breast carcino-
mas, suggesting a tumor-promoting function 
of ZBTB7A [7, 10, 11, 13-15]. On the other 
hand, reduced ZBTB7A expression has been 
associated with worse prognosis in colorectal 
carcinoma, malignant melanoma, diffuse large 
B-cell lymphoma, and acute myeloid leukemia, 
implicating its tumor-suppressive role [12, 
16-18]. The mechanism of ZBTB7A’s action 
appears to be versatile depending on the cell 
type. For example, ZBTB7A is oncogenic by tran-
scriptionally repressing the tumor suppressor 
alternative reading frame in lymphoma cells 
and by transcriptionally activating membrane 
type 1 matrix metalloproteinase in ovarian car-
cinoma cells [10, 12]. The tumor-suppressive 
function of ZBTB7A occurs through transcrip-
tional repression of glycolytic genes and mela-
noma cell adhesion molecule (MCAM) or th- 
rough indirect inhibition of a SOX9-dependent 
oncogenic pathway [16-19]. Deletion and inac-
tivating mutations [8, 16, 18], as well as sup-
pression by microRNA [11, 19, 20], have been 
suggested to contribute to the reduced ZBTB7A 
expression.
Three previously published reports describe 
ZBTB7A expression in breast carcinoma [4, 14, 
15]. In two of these reports, ZBTB7A protein 
was overexpressed in a subset of invasive duc-
tal carcinomas (IDCs) and associated with a 
worse prognosis [14, 15]. We revisited the 
issue with our cohort of 196 IDC cases, giving 
a detailed examination on the immunohisto-
chemical expression of ZBTB7A and analyzing 
its possible associations with clinicopathologi-
cal characteristics and patient outcome.
Materials and methods
Patient specimens and tissue microarray 
construction
The breast cancer tissue microarray used in 
this study has been previously described [21]. 
Briefly, the surgically resected specimens were 
fixed in 10% neutral buffered formalin, pro-
cessed, and embedded in paraffin using a 
standard protocol. All available hematoxylin 
and eosin-stained slides were reviewed by 
two Board-certified pathologists specialized in 
breast pathology, and the two most representa-
tive tumor areas were carefully selected and 
marked on individual formalin-fixed, paraffin-
embedded tissue blocks. Two tumor tissue 
cores (2 mm in diameter) were then obtained 
from each specimen and manually arrayed in 
recipient paraffin blocks. The tissue microarray 
consisted of 196 IDC cases. Nine cases were 
recurrent tumors, which were excluded from 
the survival analysis. The recurrence and sur-
vival status was updated by electronic medical 
record review for each included patient as of 
September 1, 2016. The histological grade of 
IDC had been determined according to the 
modified Bloom-Richardson grading system. 
The stage was based on the 7th American Joint 
Committee on Cancer staging manual. The 
study (2016-06-036) was reviewed and ap- 
proved by the Institutional Review Board of the 
Kangbuk Samsung Hospital (Seoul, Republic of 
Korea).
Immunohistochemistry
Immunohistochemical staining was performed 
on 3 μm-thick tissue microarray block sections. 
Briefly, the sections were dehydrated and depa-
raffinized in xylene and then rehydrated in a 
graded series of alcohol solutions. We used 
primary antibodies against ZBTB7A (1:200, 
polyclonal; Novus Biologicals, Littleton, CO, 
USA), estrogen receptor (ER; 1:200, clone SP1; 
LabVision Corporation, Fremont, CA, USA), pro-
gesterone receptor (PR; 1:200, clone PgR 636; 
DakoCytomation, Glostrup, Denmark), and hu- 
man epidermal growth factor receptor 2 (HE- 
R2; 1:200, clone SP3, LabVision Corporation). 
Immunostaining was performed using a com-
pact polymer method (Bond Intense Detection 
Kit; Leica Biosystems, Newcastle upon Tyne, 
UK). The primary antibodies were detected with 
Dako EnVision+ Systems, HRP (DakoCytoma- 
tion), according to the manufacturer’s instruc-
tions. The Dako EnVision+ Detection Systems, 
Peroxidase/DAB (DakoCytomation) was used 
for chromogenic visualization. The slides were 
then counterstained with hematoxylin and cov-
erslipped. The expression status of ER, PR, and 
HER2 was assessed using the same methods 
as those described previously [21]. ER and PR 
status was assessed using the Allred scoring 
method [22]. HER2 expression was evaluated 
using American Society of Clinical Oncology/
College of American Pathologists guideline rec-
ommendations [23]. In cases with equivocal 
HER2 staining (score 2), silver in situ hybridiza-
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tion was performed to determine HER2 gene 
status. For ZBTB7A expression, the nuclear 
and/or cytoplasmic staining was separately 
assessed. The nuclear reactivity was scored as 
the percentage of positive nuclei among the 
tumor cells. The histogram of nuclear percent-
age score was roughly bimodal with a trough 
at 65%. Therefore, nuclear expression was 
stratified into low and high with a 65% cutoff. 
Cytoplasmic staining was scored as 1 (absent 
or weak), 2 (moderate), or 3 (strong) and fur- 
ther dichotomized as low (score 1-2) and high 
(score 3) expression. In IDC cores where ductal 
carcinoma in situ (DCIS) and/or non-neoplastic 
ducts coexisted, nuclear and cytoplasmic sc- 
ores for DCIS/non-neoplastic ducts were docu-
mented along with those for IDC.
Statistical analysis
The Chi-square test, Fisher’s exact test, or lin-
ear-by-linear association test was performed 
to determine the correlation between ZBTB7A 
expression status and clinicopathological char-
acteristics. Overall survival (OS) was defined as 
the period from the first tumor resection to dis-
ease-specific death. Recurrence-free survival 
(RFS) was the time between the first tumor 
resection and the first radiological detection of 
recurrence or metastasis. Days to last follow-
up replaced OS and RFS for censored cases. 
Univariate and multivariate survival analyses 
were used to examine the prognostic signifi-
cance of ZBTB7A expression. Curves for OS and 
RFS were drawn according to the Kaplan-Meier 
method, and differences were analyzed using 
the log-rank test for univariate survival analy-
sis. Multivariate survival analysis was per-
formed for parameters that achieved statisti- 
cal significance in univariate survival analysis, 
using the Cox proportional hazards model (95% 
confidence interval) with a backward stepwise 
elimination method. Statistical analyses were 
performed using PASW Statistics for Win- 
dows (version 18.0; IBM SPSS, Chicago, IL, 
USA). Statistical significance was defined as a 
p-value of <0.05.
Results
ZBTB7A expression and its association with 
clinicopathological characteristics
Representative photomicrographs of ZBTB7A 
immunostaining in normal breast tissue and 
IDC are shown in Figure 1. ZBTB7A immunore-
activity was observed in the ductal epithelium 
of normal breast tissue and the peri-tumoral 
non-neoplastic ducts. In normal breast tissue, 
most of the ductal epithelial cells showed mod-
erate nuclear ZBTB7A immunoreactivity. The 
median value of the nuclear percentage score 
in normal breast tissue was 70%. The myoepi-
thelial cells occasionally displayed nuclear 
ZBTB7A expression. In IDC tissues, nuclear 
staining ranged from null to near 100% in dif-
ferent tumors (median, 30%). Applying a cut- 
off of 65% for nuclear staining, 76 of 196 
IDC cases (38.8%) were classified as having 
high nuclear ZBTB7A expression, and the re- 
maining 120 cases (61.2%) were classified as 
having low nuclear ZBTB7A expression. Cyto- 
plasmic ZBTB7A staining in IDCs was strong 
in 28.1% (55/196) and weak-to-moderate in 
71.9% (141/196). There was an inverse rela-
tionship between the nuclear and cytoplasmic 
ZBTB7A expression in IDC (P=0.009). In cores 
where DCIS coexisted with IDC (58 cases), the 
ZBTB7A expression pattern of DCIS was mostly 
indistinguishable from that of IDC.
The association between ZBTB7A expression 
and clinicopathological characteristics of IDC 
patients was analyzed. Low nuclear ZBTB7A 
Figure 1. Representative photomicrographs of zinc finger and BTB domain containing 7A (ZBTB7A) immunostaining. 
A. Nuclear ZBTB7A expression in the ductal epithelium of normal breast tissue. B. High nuclear ZBTB7A expression 
in breast cancer tissue. C. Low nuclear ZBTB7A expression in breast cancer tissue.
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expression in IDC was significantly associated 
with larger tumor size (P=0.017), higher histo-
logical grade (P<0.001), ER negativity (P< 
0.001), PR negativity (P=0.001), triple negativ-
ity (P<0.001), and recurrence (P=0.044; Table 
1). No statistically significant association was 
found for other clinicopathologic characteris-
tics, including age, pathological T stage, patho-
logical N stage, stage group, or lymphovascular 
invasion. In contrast with the nuclear ZBTB7A 
pression (P=0.009) were significant predictors 
of poor RFS. Low nuclear ZBTB7A expression 
was found to independently predict RFS (haz-
ard ratio =3.432, 95% confidence interval 
=1.364-8.637; Table 2). Cytoplasmic ZBTB7A 
expression did not affect OS or RFS.
Discussion
Breast cancer is the most common malignancy 
in women worldwide. Various histological types 
Table 1. Association between zinc finger and BTB domain contain-
ing 7A (ZBTB7A) expression and clinicopathological characteristics 
of invasive ductal carcinoma of the breast
Characteristic Total, n 
Nuclear ZBTB7A 
expression, n (%) p-Value
Low High
Age (years) >40 32 23 (71.9) 9 (28.1) 0.176
≤40 154 97 (59.1) 67 (40.9)
Tumor size (cm) >2 106 73 (58.9) 33 (31.1) 0.017*
≤2 90 47 (52.2) 43 (47.8)
Histological grade 1 55 22 (40.0) 33 (60.0) <0.001*
2 80 53 (66.3) 27 (33.8)
3 61 45 (73.8) 16 (26.2)
Pathological T stage pT1 92 52 (56.5) 40 (43.5) 0.227
pT2 99 65 (65.7) 34 (34.3)
pT3 4 2 (50.0) 2 (50.0)
pT4 1 1 (100.0) 0 (0)
Pathological N stage pN0 106 64 (60.4) 42 (39.6) 0.355
pN1 57 33 (57.9) 24 (42.1)
pN2 17 11 (64.7) 6 (35.3)
pN3 16 12 (75.0) 4 (25.0)
Distant metastasis Present 18 11 (61.1) 7 (38.9) 0.992
Absent 178 109 (61.2) 69 (38.9)
Stage I 65 35 (53.8) 30 (46.2) 0.126
II 97 62 (63.9) 35 (36.1)
III 33 22 (66.7) 11 (33.3)
IV 1 1 (100.0) 0 (0.0)
ER Positive 144 74 (51.4) 70 (48.6) <0.001*
Negative 52 46 (88.5) 6 (11.5)
PR Positive 131 69 (52.7) 62 (47.3) <0.001*
Negative 65 51 (78.5) 14 (21.5)
HER2 Positive 54 38 (70.4) 16 (29.6) 0.105
Negative 142 82 (57.7) 60 (42.3)
Triple negativity Yes 26 25 (96.2) 1 (3.8) <0.001*
No 170 95 (55.9) 75 (44.1)
Recurrence Yes 29 23 (79.3) 6 (20.7) 0.044*
No 161 96 (59.6) 65 (40.4)
ER: Estrogen receptor; PR: Progesterone receptor; HER2: human epidermal growth 
factor receptor 2; ZBTB7A: zinc finger and BTB domain containing 7A. *Statistically 
significant.
expression, cytoplasmic ZB- 
TB7A expression showed no 
significant associations with 
clinicopathological characte- 
ristics.
Effects of ZBTB7A expression 
on outcome of patients with 
IDC
The median follow-up time 
was 87 months. The 5-year 
OS and RFS rate was 96.4% 
and 88.5%, respectively. Uni- 
variate analysis of OS reve- 
aled that distant metastasis 
(P<0.001), advanced stage 
(P=0.038), and triple negati- 
vity (P=0.043) significantly 
predicted poor OS (Table 2). 
There was no significant dif-
ference in OS according to 
nuclear ZBTB7A expression 
status (Figure 2A). The differ-
ence in OS according to the 
higher histologic grade show- 
ed marginal significance (P= 
0.063, representatively). Mul- 
tivariate analysis of OS re- 
vealed that distant metasta-
sis was a significant predic- 
tor of poor OS (P<0.001). Uni- 
variate analysis of RFS re- 
vealed that distant metasta-
sis (P<0.001) and triple nega-
tivity (P=0.033) were signifi-
cant predictors of poor RFS 
(Table 2). The difference in 
RFS according to the nuclear 
ZBTB7A expression status 
showed marginal significan- 
ce (P=0.069; Figure 2B). In 
multivariate analysis of RFS, 
distant metastasis (P<0.001) 
and low nuclear ZBTB7A ex- 
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of breast cancer have been reported, with IDC 
being the most frequently occurring type [24, 
25]. The immunohistochemical expression of 
ER, PR, and HER2 has been widely used for 
predicting the prognosis of breast cancer and 
for providing therapeutic strategies [26]. Since 
Perou et al. [27] reported the molecular fea-
tures of breast cancer cells in 2000, the 
improvements in molecular techniques have 
provided a framework to establish molecular 
subtypes, namely luminal A; luminal B (HER2-
negative); luminal B (HER2-positive), HER2 sub-
type; basal phenotype; and five negative phe-
notypes [27-29]. Breast cancer-expressed ho- 
rmonal receptors, including ER and PR, or 
amplification of HER2, have been used in vari-
ous targeted treatment approaches [30, 31]. 
However, the effort has been devoted to iden- 
tifying factors of prognostic and therapeutic 
significance in IDC, one of which is ZBTB7A. 
Table 2. Factors predicting shortened overall and recurrence-free survival of patients with invasive 
ductal carcinoma of the breast
Characteristic
Overall survival Recurrence-free survival
Univariate Multivariate Univariate Multivariate
p-Value p-Value Hazard ratio  
(95% confidence interval)
p-Value p-Value Hazard ratio  
(95% confidence interval)
Age >40 years 0.885 Not applicable 0.819 Not applicable
Higher histological grade 0.063 0.069 6.939 (0.857-56.182) 0.551 Not applicable
pT2-4 0.592 Not applicable 0.736 Not applicable
Lymph node metastasis 0.437 Not applicable 0.493 Not applicable
Distant metastasis <0.001* <0.001* 65.143 (15.980-265.551) <0.001* <0.001* 38.390 (16.464-89.520)
Advanced stage 0.038* 0.703 1.515 (0.179-12.854) 0.106 Not applicable
ER negativity 0.119 Not applicable 0.222 Not applicable
PR negativity 0.143 Not applicable 0.098 0.626 0.780 (0.288-2.115)
HER2 negativity 0.902 Not applicable 0.357 Not applicable
Triple negativity 0.043* 0.179 2.289 (0.683-7.669) 0.033* 0.446 1.409 (0.583-3.404)
Low nuclear ZBTB7A expression 0.843 Not applicable 0.069 0.009* 3.432 (1.364-8.637)
ER: Estrogen receptor; PR: Progesterone receptor; HER2: human epidermal growth factor receptor 2; ZBTB7A: zinc finger and BTB domain containing 7A. *Statistically 
significant.
Figure 2. Prognostic significance of zinc finger and BTB domain containing 7A (ZBTB7A) expression in patients with 
breast cancer. Kaplan-Meier curves illustrating (A) overall survival and (B) recurrence-free survival.
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ZBTB7A mRNA and protein have been identified 
in both normal and cancerous tissues of multi-
ple organs, and the expression of ZBTB7A in 
cancer has provided ambivalent results. Some 
researchers have reported that ZBTB7A has 
unfavorable prognostic effects in several malig-
nancies by suppressing p14ARF or upregulat-
ing survivin [7, 10, 11, 13-15]. On the other 
hand, favorable prognostic effects of ZBTB7A 
expression have also been reported. Reduced 
ZBTB7A expression has been associated with 
worse prognosis through affecting another 
pathway such as upregulation of MCAM or re- 
pression of glycolysis or survivin, implicating 
its tumor-suppressive role [12, 16-18]. Based 
on these reports, ZBTB7A appears to play sev-
eral different roles in malignancy through vari-
able molecular pathways.
In this study, the immunohistochemical expres-
sion of ZBTB7A was analyzed in patients with 
IDC. Low nuclear ZBTB7A expression was sig-
nificantly associated with aggressive oncogenic 
behavior including larger tumor size, higher his-
tological grade, and recurrence. In addition, 
reduced ZBTB7A expression in the tumor cell 
nuclei correlated with negative ER and PR 
expression. The triple-negative phenotype was 
more frequently observed in patients whose 
tumors showed low nuclear ZBTB7A expres-
sion. ZBTB7A expression was not statistically 
associated with OS. Only distant metastasis 
was an independent prognostic factor for OS. 
No clinicopathological parameters influenced 
the RFS except distant metastasis and triple 
negativity. Even though RFS of patients with 
low nuclear ZBTB7A expression was lower than 
that of patients with high nuclear ZBTB7A ex- 
pression, the difference was statistically mar-
ginally significant. Nevertheless, in multivariate 
analysis for RFS, low nuclear ZBTB7A expres-
sion was found to independently predict RFS, 
suggesting that ZBTB7A expression is a novel 
prognostic biomarker for RFS of patients with 
IDC. Our results agree with those of previous 
studies demonstrating an association between 
low ZBTB7A expression and aggressive onco-
genic behavior in non-small cell lung cancer, 
ovary carcinoma, gastric carcinoma, and hepa-
tocellular carcinoma [7, 10, 11, 13].
In conclusion, we demonstrate that low nuclear 
ZBTB7A expression is associated with unfavor-
able clinicopathological characteristics includ-
ing larger tumor size, higher histological grade, 
negativity for ER and PR, triple negativity, and 
recurrence in IDC. In addition, there was a 
significant relationship between low nuclear 
expression of ZBTB7A and poor RFS. Our data 
suggest that nuclear ZBTB7A expression is a 
novel prognostic biomarker for patients with 
breast cancer.
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